Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens


CARTITUDE-4 is the... | June 6, 2023

Related Keywords

Japan ,China ,United States ,New Jersey ,American ,Ying Huang ,Hemophagocytic Lymphohistiocytosis ,European Hematology Association ,Janssen Biotech Inc ,Community Register Of Orphan Medicinal Products ,Exchange Commission On ,Twitter ,Linkedin ,American Cancer Society ,European Commission ,Medicinal Devices Agency ,Data Monitoring Committee ,American Society Of Clinical Oncology ,Drug Administration ,Japan Ministry Of Health ,European Commission For The Treatment Of Patients ,Legend Biotech Corporation ,Legend Biotech ,Biologics License Application ,Chief Executive Officer ,Clinical Oncology ,Annual Meeting ,New England Journal ,Hematology Association ,Hybrid Congress ,Independent Data Monitoring Committee ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Mediated Myelitis ,Nerve Palsies ,Recurrent Cytopenias ,Igg Hypersensitivity Reactions ,Janssen Biotech ,Use Machines ,Prescribing Information ,Boxed Warning ,Breakthrough Therapy Designation ,Orphan Drug Designation ,European Medicines Agency ,Orphan Medicinal Products ,Private Securities Litigation Reform Act ,Annual Report ,Exchange Commission ,Standard Care ,Lenalidomide Refractory Multiple ,Adult Patients ,Refractory Multiple ,Accessed March ,Granted Conditional Approval ,Receives Approval ,Community Register ,Orphan Medicinal ,Statistics About Multiple Myeloma ,Legend Biotech Corporation Stock Exchange ,News ,Information ,Press Release ,The ,Application ,Us ,Upported ,Y ,Hase , ,Which ,Howed ,Significant ,Improvement ,N ,Primary ,Ndpoint ,F ,Survival ,Ompared ,O ,Standard ,S Legn Us52490g1022 ,